moneyheap
BIIB · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Biogen Inc. Common Stock (BIIB) stock moving?
Biogen's recent news is dominated by analyst activity following its Q3 2026 results, released Oct 28, which beat estimates and narrowed the FY2026 EPS outlook. Since then, multiple brokers have reaffirmed positive ratings and raised targets: Piper Sandler to $305, Guggenheim to $300, HC Wainwright to $270, Canaccord to $272 and Argus upgraded to Buy at $280. Morgan Stanley (Equal-Weight, $238) and Wedbush (Neutral, $225) sit at the low end, so the spread of targets is wide but the bias is upward. Company news is mixed: the dapirolizumab pegol lupus data are post-hoc analyses rather than a new pivotal readout, the Canadian private payer coverage for Zurzuvae is incremental, and the CTAD Alzheimer's data are still ahead. The price has been range-bound between about $240 and $261 over the last 14 sessions, with a Nov 10 close of $253.25, roughly unchanged from $253.84 on Oct 22. The Oct 28 results day brought the heaviest volume (2.49M shares) and a close of $244.05, which was recovered by Nov 9 (close $254.87, intraday high $261). Volume has faded to 735K on Nov 10, the lowest in the window, and the stock is trading near its VWAP, so the post-earnings move looks largely absorbed.
News behind the analysis
- Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305Piper Sandler kept its Overweight rating and raised its price target to $305, the highest target among the recent analyst updates.
- UCB and Biogen Present New Clinical Data for Dapirolizumab Pegol at ACR Convergence 2026UCB and Biogen presented new data on dapirolizumab pegol, an investigational lupus biologic, at ACR Convergence 2026.
- UCB And Biogen Report Dapirolizumab Pegol Plus SOC Associated With Higher Response Versus Placebo On Novel TRM-SLE And Greater Sustained Low Disease Activity In Post-Hoc Phase 3 PHOENYCS GO AnalysesPost-hoc Phase 3 PHOENYCS GO analyses linked dapirolizumab pegol plus standard of care to higher response than placebo on a novel lupus response measure. These are post-hoc results, not a new pivotal readout.
- Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following ChildbirthMany Canadian group benefit health plans now reimburse ZURZUVAE (zuranolone) for moderate or severe postpartum depression, widening patient access.
- HC Wainwright & Co. Maintains Biogen at Buy, Raises Price Target to $270HC Wainwright reaffirmed its Buy rating and raised its price target from $251 to $270.
- Guggenheim Maintains Buy on Biogen, Raises Price Target to $300Guggenheim kept its Buy rating and raised its price target to $300.
- Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272Canaccord Genuity kept its Buy rating and lifted its price target to $272.
- Argus Research Upgrades Biogen to Buy, Announces $280 Price TargetArgus Research upgraded Biogen to Buy with a $280 price target.
- These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 ResultsBiogen beat Q3 estimates and narrowed its FY2026 EPS outlook, prompting analysts to raise targets to as high as $290; shares dipped 0.3% premarket.
- Biogen to Present New Alzheimer's Disease Portfolio Data at 19th CTAD ConferenceBiogen will present new Alzheimer's pipeline data, including the Phase 2 CELIA study of diranersen and lecanemab, at the upcoming CTAD conference.
About Biogen Inc. Common Stock
Biogen is a Cambridge, Massachusetts biotech company best known for its multiple sclerosis drugs. It also has a big presence in other brain and nerve diseases, including the Alzheimer's drug LEQEMBI (sold with Eisai) and the spinal muscular atrophy drug SPINRAZA, and its May 2026 purchase of Apellis added eye and rare-disease drugs.
How it makes money
Most of its revenue comes from selling its own drugs. These include its multiple sclerosis medicines (TYSABRI, VUMERITY, TECFIDERA, AVONEX, PLEGRIDY), which used to be its largest business but are shrinking as cheaper copies arrive. Its newer drugs include SPINRAZA, SKYCLARYS, QALSODY and ZURZUVAE, plus SYFOVRE and EMPAVELI from the Apellis deal. Biogen also gets a share of the profits and sales from LEQEMBI through its partnership with Eisai, royalties and profit shares from Roche/Genentech drugs such as OCREVUS, and sales of cheaper versions of other companies' biologic drugs (biosimilars). Quarterly revenue was about $2.8 billion in Q3 2026.
What usually moves BIIB
- Alzheimer's drug LEQEMBI sales and uptake
- Results from late-stage drug trials and FDA decisions (e.g., litifilimab in lupus)
- Loss of sales in older MS drugs to cheaper generic and biosimilar versions
- Growth of drugs from the Apellis deal and other acquisitions or licensing deals
- Drug pricing policy and Medicare negotiation